News | January 12, 2022
Veristat supported marketing applications for 12 % of all FDA Novel Drug Approvals in 2021
This surpasses the number of approvals supported in 2020
This surpasses the number of approvals supported in 2020
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Key takeaways of recent quarter & conference call highlights
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Subscribe To Our Newsletter & Stay Updated
